Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,160.31 +12.39 0.58%
FTSE 100 5,391.14 +34.80 0.65%
DAX 6,396.84 +73.65 1.16%
Ticker Volume Price Price Delta
Nikkei 8,657.08 +63.93 0.74%
TOPIX 727.03 +5.92 0.82%
Hang Seng 19,055.50 +254.47 1.35%
Gold 1,556.70 -0.92%
EUR-USD 1.2495 -0.0638%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,391.14 +0.65%
STOXX 50 2,160.31 +0.58%
DAX 6,396.84 +1.16%
Oil (WTI) 90.88 +0.02%
U.S. 10-year 1.745% +0.007
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: -
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Cephalon Inc

CEPH:US

Acquired

As of 10/13/2011.

Cephalon Inc (CEPH:US) was acquired by TEVA:IT


Company Profile

Cephalon Incorporated provides biopharmaceutical products. The Company develops and markets medications to treat central nervous system disorders, cancer, and pain. Cephalon serves the healthcare industry in the United States, Europe, and Australia.

Advertisement